Clinical trials of human mesenchymal stem cells to support hematopoietic stem cell transplantation

Genetic Engineering of Mesenchymal Stem Cells

Volumn , Issue , 2006, Pages 151-162

  Koc O N ^a  

^a Ireland Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889701694     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/1-4020-3959-X_9     Document Type: Chapter

References (44)

1. Ko̧c ON, Gerson S, Cooper B, et al. Rapid hematopoietic recovery after co-infusion of autologous cultureexpanded human mesenchymal stem cells (hMSCs) and PBPCs in breast cancer patients receiving high dose chemotherapy. J Clin Oncol. 2000:18:307-316.
2. Lennon DP, Haynesworth SE, Bruder SP, Jaiswal N, Caplan AI. Development of a serum screen for mesenchymal progenitor cells from bone marrow. In Vitro Cell Dev Biol. 1996;32:602-611.
3. Galotto M, Berisso G, Delfino L, et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol. 1999;27:1460-1466.
4. Barbot C, Rice A, Vanes I, Mahon FX, Jazwiec B, Reiffers J. Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation recipients. Nouv Rev Fr Hematol. 1994;36:325-331.
5. Fried W, Kedo A, Barone J. Effects of cyclophosaphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma. Cancer Res. 1977;37:1205-1209.
6. McManus PM, Weiss L. Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies. Blood. 1984;64:1036-1041.
7. Uhlman DL, Verfaillie C, Jones RB, Luikart SD. BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis. Br J Haematol. 1991;78:3304-3309.
8. Toksoz D, Zsebo K, Smith K, et al. Support of human hematopoiesis in long term bone marrow cultures by murine stromal cells selectively expressing the membrane bound and secreted forms of the human homologue of the steel gene product, stem cell factor. Proc Natl Acad Sci USA. 1992;89:7350-7354.
9. Clark B, Keating A. Biology of bone marrow stroma. Ann NY Acad Sci. 1995;770:70-88.
10. Haynesworth S, Baber M, Caplan A. Cytokine expression by human marrow derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1a. J Cell Physiol. 1996;166:585-592.
11. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol. 1998;176:186-192.
12. Majumdar M, Thiede M, Haynesworth S, Bruder S, Gerson S. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-termhematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res. 2001;9:841-848.
13. Kadereit S, Deeds L, Haynesworth S, et al. Mesencymal stem cell as a feeder layer during short-termumbilical cord blood in vivo expansion increases early hematopoietic progenitors. Stem Cells. 2002;20:573-582.
14. Klyushnenkova E, Mosca J, McIntosh K. Human mesenchymal stem cells suppress allogeneic T cell responses in vitro: implications for allogeneic transplantation. Blood. 1998;92:642a.
15. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.
16. Le Blanc K, Tammik L, Sundberg B, Haynesworth S, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scan J Immunol. 2003;57:11-20.
17. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389-397.
18. Maitra B, Szekely E, Gjini K, Laughlin MJD, Haynesworth S, Ko̧c ON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2003.
19. Farida D, Pascale P, Claire B, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003.
20. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722-3729.
21. Anklesaria P, Kase K, Glowacki J, et al. Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. Proc Natl Acad Sci USA. 1987;1987:7681-7685.
22. Almeida-Porada G, Flake A, Hudson A, Zanjani E. Co transplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol. 1999;27:1569-1575.
23. Noort WA, Kruisselbrink AB, Anker PS, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34 (+) cells in NOD/SCID mice. Exp Hematol. 2002;30:870-878.
24. Angelopoulou M, Novelli E, Grove J, et al. Co transplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol. 2003;31:413-420.
25. Almeida-Porada G, Porada C, Tran N, Zanjani E. Co transplantation of human stromal cell progenitors into preimmune ftal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood. 2000;95:3620-3627.
26. Ishida T, Inaba M, Hisha H, et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol. 1994;152:3119-3127.
27. El-Badri N, Wang BC, Good R. Osteoblasts promote engraftment of allogeneic hematopoietic stem cells. Exp Hematol. 1998;29:110-116.
28. Kaufman C, Colson Y, Wren S, Watkins S, Simmons R, Ildstad S. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84:2436-2446.
29. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;72:1653-1655.
30. Simmons PJ, Przepiorka D, Thomas ED, Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature. 1987;328:429-432.
31. Ko̧c ON, Peters C, Raghavan S, et al. Bone marrow derived mesenchymal stem cells of patients with lysosomal and peroxisomal storage diseases remain host type following allogeneic bone marrow transplantation. Exp Hematol. 1999;27:1675-1681.
32. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrowderived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309-313.
33. Rombouts W, Ploemacher R. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 2003;17:160-170.
34. Mackenzie T, Flake A. Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. Blood Cells Mol Dis. 2001;27:601-604.
35. Lazarus H, Haynesworth S, Gerson S, Rosenthal N, Caplan A. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therpeutic use. Bone Marrow Transplant. 1995;16:557-564.
36. Ko̧c ON, Day J, Nieder M, Gerson S, Lazarus H, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 2002;30:215-222.
37. Lazarus H, Curtin P, Devine S, McCarthy P, Holland K, Moseley A A B. Role of mesenchymal stem cells in allogeneic transplantation: early phase I clinical results. Blood. 2000;96:392a.
38. Horwitz E, Gordon P, Koo W, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99:8932-8937.
39. Lee S, Jang J, Cheong J, et al. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and cultureexpanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol. 2001;118:1128-1131.
40. MacMillan L, Ramsay N, Atkinson K, Wagner J. Ex vivo culture-expanded parental haploidentical mesenchymal stem cells promote engraftment in recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Blood. 2002;100:836a.
41. Krivit W, Day J, Koc ON, Atkinson K. Multiple mesenchymal stem cell (allogen) infusions in patients with metachromatic leukodystrophy: safety of infusions and stability of nerve conduction velocities. Blood. 2002;100:524a.
42. Cahill R, Jones O, Mueller T, El-Badri N, Good R. Replacement of recipient stromal/mesenchymal cells after bone marrowtransplant using bone fragments and cultured osteoblast like cells. Blood. 2002;100:63a.
43. Frassoni F, Labopin M, Bacigalupo A, et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hemopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched pair analysis. Bone Marrow Transplant. 2002;29:S2.
44. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815-1822.